TRAW Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Traws Pharma Inc (TRAW.O) is -0.77, compared to its 5-year average forward P/E of -12.79. For a more detailed relative valuation and DCF analysis to assess Traws Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.79

Current PE

-0.77

Overvalued PE

35.81

Undervalued PE

-61.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.65

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.35

Undervalued EV/EBITDA

-3.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

173.80

Current PS

0.00

Overvalued PS

449.00

Undervalued PS

-101.39

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TRAW News & Events

Events Timeline

No data

News

9.0

2025-12-17Benzinga

Traws Pharma's Oral COVID Treatment Demonstrates Results Similar to Paxlovid

3.5

2025-12-17Globenewswire

Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment

9.0

2025-12-17Newsfilter

Traws Pharma's Ratutrelvir Shows Favorable Tolerability in COVID-19 Treatment

People Also Watch

Frequently Asked Questions

What is Traws Pharma Inc (TRAW) stock price today?

The current price of TRAW is 1.41 USD — it has increased 5.22 % in the last trading day.

What is Traws Pharma Inc (TRAW)'s business?

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

What is the price predicton of TRAW Stock?

Wall Street analysts forecast TRAW stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRAW is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Traws Pharma Inc (TRAW)'s revenue for the last quarter?

Traws Pharma Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Traws Pharma Inc (TRAW)'s earnings per share (EPS) for the last quarter?

Traws Pharma Inc. EPS for the last quarter amounts to -0.34 USD, decreased -96.14 % YoY.

What changes have occurred in the market's expectations for Traws Pharma Inc (TRAW)'s fundamentals?

The market is revising No Change the revenue expectations for Traws Pharma, Inc. (TRAW) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -54.95%.

How many employees does Traws Pharma Inc (TRAW). have?

Traws Pharma Inc (TRAW) has 7 emplpoyees as of January 09 2026.

What is Traws Pharma Inc (TRAW) market cap?

Today TRAW has the market capitalization of 10.71M USD.